Daan van den Broek
Overview
Explore the profile of Daan van den Broek including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
61
Citations
750
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
11.
Schepens E, Al-Mamgani A, Karssemakers L, van den Broek D, van den Brekel M, Lopez-Yurda M
Otolaryngol Head Neck Surg
. 2023 Sep;
170(2):422-430.
PMID: 37694613
Objective: to determine if the tumor marker squamous cell carcinoma antigen (SCC-Ag) observed over time may contribute to the early detection of recurrence, metastasis, and second primary tumors in the...
12.
Liefaard M, Moore K, Mulder L, van den Broek D, Wesseling J, Sonke G, et al.
Br J Cancer
. 2023 Jul;
129(4):734.
PMID: 37488450
No abstract available.
13.
Rozeman E, Versluis J, Sikorska K, Hoefsmit E, Dimitriadis P, Rao D, et al.
J Immunother Cancer
. 2023 Jul;
11(7).
PMID: 37479483
Background: Continuous combination of MAPK pathway inhibition (MAPKi) and anti-programmed death-(ligand) 1 (PD-(L)1) showed high response rates, but only limited improvement in progression-free survival (PFS) at the cost of a...
14.
van Dorp J, Pipinikas C, Suelmann B, Mehra N, van Dijk N, Marsico G, et al.
Nat Med
. 2023 Jul;
30(1):304.
PMID: 37460757
No abstract available.
15.
Antunes-Ferreira M, DAmbrosi S, Arkani M, Post E, In t Veld S, Ramaker J, et al.
Sci Rep
. 2023 Jun;
13(1):9359.
PMID: 37291189
Liquid biopsy approaches offer a promising technology for early and minimally invasive cancer detection. Tumor-educated platelets (TEPs) have emerged as a promising liquid biopsy biosource for the detection of various...
16.
Muller M, Best M, van der Noort V, Hiltermann T, Niemeijer A, Post E, et al.
Tumour Biol
. 2023 Jun;
46(s1):S327-S340.
PMID: 37270827
Background: Anti-PD-(L)1 immunotherapy has emerged as a promising treatment approach for non-small cell lung cancer (NSCLC), though the response rates remain low. Pre-treatment response prediction may improve patient allocation for...
17.
Wessels P, Boelens M, Monkhorst K, Sonke G, van den Broek D, Brandsma D
J Neurooncol
. 2023 Feb;
162(1):1-13.
PMID: 36820955
Acquired mutations or altered gene expression patterns in brain metastases (BM) and/or leptomeningeal metastases (LM) of breast cancer may play a role in therapy-resistance and offer new molecular targets and...
18.
Liefaard M, Moore K, Mulder L, van den Broek D, Wesseling J, Sonke G, et al.
Br J Cancer
. 2023 Feb;
128(8):1572-1581.
PMID: 36765174
Background: Studies have shown that blood platelets contain tumour-specific mRNA profiles tumour-educated platelets (TEPs). Here, we aim to train a TEP-based breast cancer detection classifier. Methods: Platelet mRNA was sequenced...
19.
van Dorp J, Pipinikas C, Suelmann B, Mehra N, van Dijk N, Marsico G, et al.
Nat Med
. 2023 Feb;
29(3):588-592.
PMID: 36732628
Cohort 1 of the phase 1B NABUCCO trial showed high pathological complete response (pCR) rates with preoperative ipilimumab plus nivolumab in stage III urothelial cancer (UC). In cohort 2, the...
20.
Kramer A, Schuuring E, Vessies D, van der Leest P, Geerlings M, Rozendal P, et al.
J Mol Diagn
. 2022 Nov;
25(1):36-45.
PMID: 36402278
Circulating tumor DNA (ctDNA) is a promising new biomarker with multiple potential applications in cancer care. Estimating total cost of ctDNA testing is necessary for reimbursement and implementation, but challenging...